期刊文献+

血、尿内皮素1及白介素6应用于动脉粥样硬化性肾动脉狭窄筛查的初步探讨

Application of serum and urinary endothelin-1, interleukin-6 assay in screening atherosclerotic renal artery stenosis
原文传递
导出
摘要 目的探讨血及尿内皮素1(ET-1)、白介素6(IL-6)应用于动脉粥样硬化性肾动脉狭窄(ARAS)筛查的可能性。方法检测49例不同狭窄程度的ARAS患者,32例合并≥2项动脉粥样硬化危险因素的非ARAS患者及30例正常对照的血及尿ET-1、IL-6水平,构建其诊断ARAS的受试者工作特征曲线(ROC曲线)。结果尿ET-1、尿IL-6及尿ET-1/血ET-1比值与肾动脉狭窄程度相关。在用于诊断狭窄程度≥50%的ARAS患者时,其ROC曲线下面积分别为0.792、0.756及0.779。尿ET-1以6.72 ng/mmol肌酐为界值时,诊断ARAS的敏感度为80.0%,特异度为72.8%。尿ET-1/血ET-1比值以12.59为界值时,敏感度为66.7%,特异度为61.7%。而尿IL-6以23.85 ng/mmol肌酐为界值时,敏感度为73.3%,特异度为70.4%。若采用系列研究方法,尿IL-6以12.60ng/mmol肌酐为界值并联用高血压这一临床指标时,敏感度和特异度可提高至80.0%与77.8%。结论尿ET-1及尿IL-6有应用于ARAS筛查的可能性。 Objective To investigate the possibility of using serum and urinary endothelin-1 (ET-1), interleukin-6 (IL-6) assay as screening tools for atherosclerotic renal artery stenosis (ARAS). Methods Serum and urinary samples from 49 patients with ARAS, 32 cases with ≥ 2 risk factors for atherosclerosis and 30 normal controls were detected for ET-1 and IL-6 by RIA. The receiver operating characteristic (ROC) curves were then generated to assess their accuracy in screening ARAS by using selective renal angiography as golden standard. Results Urinary ET-1, urinary IL-6 and urinary-serum ratio of ET-1 in ARAS cases were higher than those in two control groups, and were all correlated with degree of renal artery stenosis. The area under the ROC curve of urinary ET-1, urinary IL-6 and urinary-serum ratio of ET-I was 0.792, 0.756 and 0.779, respectively. The sensitivity and specificity of urinary ET-1 to distinguish ARAS (I〉50%) was 80.0% and 72.8% respectively using 6.72 ng/mmol creatinine as the cut-off point. The cut-off value of ET-1 urinary-serum ratio was 12.59 with a sensitivity of 66.7% and a specificity of 61.7%. The sensitivity and specificity of urinary IL-6 were 73.3% and 70.4% respectively using 23.85 ng/mmol creatinine as the cut-off point. The sensitivity and specificity were improved to 80.0% and 77.8% respectively when using 12.60 ng/mmol creatinine as the cut-off point and combined with hypertension to perform series test. Conclusion Urinary ET-1 and urinary IL-6 could be used as screening tools for ARAS.
出处 《中华肾脏病杂志》 CAS CSCD 北大核心 2005年第11期672-676,共5页 Chinese Journal of Nephrology
基金 卫生部临床学科重点项目(20010913)
关键词 动脉粥样硬化 肾动脉狭窄 内皮素1 白介素6 诊断 Atherosclerosis Renal artery stenosis Endothelin- 1 Interleukin- 6 Diagnosis
  • 相关文献

参考文献15

  • 1Safian RD, Textor SC. Medical progress: renal-artery stenosis. N Engl J Med, 2001, 344:431-442
  • 2Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med,130:461-470.
  • 3王梅,王海燕.慢性缺血性肾脏疾病的诊断与治疗(三) 动脉粥样硬化引起的肾动脉狭窄的诊断与治疗[J].中华内科杂志,2002,41(1):56-58. 被引量:22
  • 4Dorros G, Mathiak L. Four-year follow-up of Palmaz-Schatz stent revasculization as treatment for atherosclerotic renal artery stenosis. Circulation, 1998, 98: 642-647.
  • 5Levin ER. Endothelins. N Engl J Med, 1995, 333:356-363
  • 6Firth JD, Schricker K, Ratcliffe PJ, et al. Expression of endothelins 1 and 3 in the rat kidney. Am J Physiol, 1995,269: 522-528.
  • 7Ilaria C, Amedeo MP, Loredana P, et al. Endothelin-1urinary exrestion, but not endothelin-1 plasma concentration,is increased in renovascular hypertension. J Lab Clin Med,1999, 134:386-391
  • 8Harris TB, Ferrucci L, Tracy RP, et al. Mortality risk associated with elevated interleukin-6 and C-reactive protein in old age. Am J Med, 1999, 196:506-512
  • 9Ranieri E, Gesualdo L, Petrarulo F, et al. Urinary Il-6/EGF ratio: A useful prognostic marker for the progression of renal damage in Ig A nephropathy. Kidney Int, 1996, 50:1990-2001.
  • 10Peppa-Patrikiou M, Dracopoulou M, Dacou-Voutetakis C.Urinary endothelin in adolescents and young adults with insulin-dependent diabetes mellitus: relation to urinary albumin, blood pressure, and other factors. Metabolism,1998, 47: 1408-1412.

二级参考文献13

  • 1Mailloux LU, Napolitano B, Bellucci AG, et al. Renal vascular disease causing end-stage renal Ddsease, incidence, clinical correlates, and outcomes: a 20-year clinical experience. Am J Kidney Dis, 1994, 24: 622-629.
  • 2O′Neil EA, Hansen KJ, Canzenello VJ, et al. Prevalence of ischemic nephropathy in patients with renal insufficiency. Am Surg, 1992, 58: 485-490.
  • 3Wachtell K, Ibsen H, Olsen MH, et al. Prevalence of renal artery stenosis in patients with peripheral vascular disease and hypertension. J Hum Hypertens, 1996, 10:83-85.
  • 4Olbricht CJ, Paul K, Prokop M, et al. Minimally invasive diagnosis of renal artery stenosis by spiral computed tomography angiography. Kidney Int, 1995,48:1332-1337.
  • 5Prince MR, Schoenberg SO, Ward JS, et al. Hemodynamically significant atherosclerotic renal artery stenosis: MR angiographic features. Radiology, 1997, 205:128-136.
  • 6Pedersen EB. New tools in diagnosing renal artery stenosis. Kidney Int, 2000, 57: 2657-2677.
  • 7Oliva VL, Soulez G, Lesage D, et al. Detection of renal artery stenosis with Doppler sonography before and after administration of captopril: value of early systolic rise. AJR, 1998, 170: 169-175.
  • 8Macleod M, Taylor AD, Baxter G, et al. Renal artery stenosis managed by palmaz stent insersion: technical and clinical outcome. J Hypertens, 1995, 13:1791-1795.
  • 9Boisclair C, Therasse E, Oliver VL, et al. Treatment of renal angioplasty failure by percutaneous renal artery stenting with Palmaz stents: midterm technical and clinical results. AJR, 1997, 168: 245-251.
  • 10Dorros G, Jaff M, Mathiak L, et al. Four-year follow-up Palmaz-Schatz stent revascularization as treatment for atherosclerotic renal artery stenosis. Circulation, 1998, 98:642-647.

共引文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部